Palau Pharma is seeking to in-license NCE's indicated for the treatment of inflammation and autoimmune disorders.
The company is interested in small molecules either at the late pre-clinical stage, clinical phase I, or phase IIa that have strong patent protection.
Palau Pharma would prefer the molecules to be delivered orally but would consider topical, transdermal or oral delivery with local exposure.
Licensing or acquisition.
Heidi Sisniega
Head
Business Development & Licensing
PALAU PHARMA is a product-driven specialty pharmaceutical company devoted to the discovery and development of safer medicines for the treatment of inflammatory and autoimmune conditions.
View profile© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
